NDA 214429 · Sanofi
Fexinidazole
Fexinidazole · Oral · Nitroimidazole Antimicrobial
NovelPriority reviewOrphanCDER novel approval, Jul 16, 2021: To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense
Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jul 16, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
5 Phase 3, 0 recruiting
FAERS reports
13
13 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 2, 2025.
Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Fexinidazole Tablets is a nitroimidazole antimicrobial, indicated for the treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. ( 1 ) Limitations of Use Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/µL) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options. ( 1 , 5.1 ) Limitations of Use Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/µL) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options [see Warnings and Precautions (5.1) ] .
Mechanism: Fexinidazole is an antiprotozoal drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 16, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- FEXINIDAZOLE · FEXINIDAZOLE 600MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fexinidazole" as an intervention, any sponsor and status, largest first.
- Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2Pivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT01685827 · 394 participants · Start Oct 2012 · Primary completion Nov 11, 2016
Drug: Fexinidazole; Nifurtimox and 1 more · For: Human African Trypanosomiasis (HAT); Sleeping Sickness
Sites: Batangafo, Central African Republic; Bagata, Democratic Republic of the Congo; Masi Manimba, Republic of the Congo · 10 sites in all
Drugs for Neglected DiseasesAcademic, hospital or other
NCT02169557 · 230 participants · Start Apr 30, 2014 · Primary completion Oct 9, 2016
Drug: Fexinidazole · For: Human African Trypanosomiasis (HAT)
Sites: Kinshasa, Democratic Republic of the Congo
- Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any StagePivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT03025789 · 174 participants · Start Nov 10, 2016 · Primary completion Feb 1, 2021
Drug: Fexinidazole · For: Trypanosomiasis, African; Sleeping Sickness; Trypanosomiasis; Gambian
Sites: Mbuji-Mayi, Democratic Republic of the Congo; Bagata, Democratic Republic of the Congo; Bandundu Province, Democratic Republic of the Congo · 8 sites in all
- Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas DiseasePivotal-lookingStatus unknown
Drugs for Neglected DiseasesAcademic, hospital or other
NCT02498782 · 140 participants (planned) · Start Jul 2014 · Primary completion Sep 2015
Drug: Fexinidazole; Placebo · For: Chagas Disease; Trypanosomiasis, South American; South American Trypanosomiasis and 1 more
Sites: Cochabamba, Bolivia; Tarija, Bolivia
Drugs for Neglected DiseasesAcademic, hospital or other
NCT02184689 · 125 participants · Start May 3, 2014 · Primary completion Dec 14, 2016
Drug: fexinidazole · For: Human African Trypanosomiasis (HAT)
Sites: Kinshasa, Democratic Republic of the Congo
- Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the FexinidazolePivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT00982904 · 108 participants · Start Sep 2009 · Primary completion Sep 2010
Drug: Fexinidazole/Placebo · For: Human African Trypanosomiasis
Sites: Paris, France
- Fexinidazole in Human African Trypanosomiasis Due to T. b. RhodesiensePivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT03974178 · 45 participants · Start Sep 29, 2019 · Primary completion Nov 30, 2021
Drug: Fexinidazole · For: Trypanosomiasis, African; Sleeping Sickness; Trypanosoma Brucei Rhodesiense; Infection
Sites: Rumphi, Malawi; Lwala, Uganda
Drugs for Neglected DiseasesAcademic, hospital or other
NCT03587766 · 45 participants · Start Nov 13, 2017 · Primary completion Dec 19, 2018
Drug: Fexinidazole; Placebo Oral Tablet · For: Chagas' Disease (Chronic) Nos
Sites: Barcelona, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure6
- anaemia3
- pyrexia3
- treatment failure3
- asphyxia2
- coma2
- completed suicide2
- headache2
- pneumonia2
- abdominal pain upper1
- acute kidney injury1
- acute pulmonary oedema1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Chemotherapy for second-stage human African trypanosomiasis: drugs in use.
Lutje V, Probyn K, Seixas J, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2-3, non-randomised study.
Matovu E, Nyirenda W, Eriatu A, et al. · Lancet Glob Health 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Mesu VKBK, Kalonji WM, Bardonneau C, et al. · Lancet 2018 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Pharmacokinetics and Tolerability of Fexinidazole in Subjects with Hepatic Impairment.
Gassiot M, Beaucire JP, Hays S, et al. · Clin Drug Investig 2026 · Multicenter Study, Clinical Trial, Phase I
- Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial.
Pinazo MJ, Forsyth C, Losada I, et al. · Lancet Infect Dis 2024 · Randomized Controlled Trial, Multicenter Study
- A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease.
Torrico F, Gascón J, Ortiz L, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.